Phase I trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of KOS-1584 administered weekly for 3 weeks every 4 weeks in patients with advanced solid tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2007
At a glance
- Drugs KOS 1584 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Kosan Biosciences; Roche
- 28 Feb 2007 Status change from recruiting to in progress.
- 28 Jun 2006 New trial record.